Document is current
Any future updates will be listed below
-
Authors
Zhang, Haini
Xu, Xiao
Ta, Christopher
Zurutuza, Ian
Gautam, Krishna Sharmah
Hongsermeier, Cody
Blasi, Nicole
Voorugonda, Sindhu
Mukherjee-Roy, Neije
Gao, Jinming
Sumer, Baran
Akers, Walter J.
Achilefu, Samuel
-
Funding
Funding for this research was provided by:
National Institutes of Health (NCI R01 CA211930)
National Institutes of Health (R01 CA266146)
National Institutes of Health (R01 EB030987)
Cancer Prevention and Research Institute of Texas (RR220013)
- License Information
-
More Information
Article History
Received: 25 November 2025
Accepted: 20 April 2026
First Online: 25 May 2026
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: SA is the primary inventor of CVG and LS301, which are used in this study. Other authors declare no competing financial interests. B.D.S. and J.G. are inventors of Pegsitacianine and scientific co-founders of OncoNano Medicine, Inc.
